What it Does: Administered by the Department of Justice’s Civil Division, Torts Branch, the Radiation Exposure Compensation Program (RECP) provides financial restitution to those who became seriously ill as a result of nuclear testing and uranium mining. Using a special trust fund, RECP disburses fixed payments to
eligible claimants in the following amounts:
- $50,000 to individuals residing or working “downwind” of the Nevada Test Site
- $75,000 for workers participating in above-ground nuclear weapons tests
- $100,000 for uranium mining and mill workers and ore transporters
Uranium Miners and Mill Workers
A payment of $100,000 is available to individuals who were employed in aboveground or underground uranium mines or uranium mills located in Colorado, New Mexico, Arizona, Wyoming, South Dakota, Washington, Utah, Idaho, North Dakota, Oregon and Texas at any time from January 1, 1942, to December 31, 1971. Miners must have been exposed to 40 or more working level months of radiation while employed in a uranium mine or worked for at least one year in a uranium mine during the relevant time period. Mill workers must have worked in a uranium mill for at least one year. Compensable diseases for miners and mill workers include primary lung cancer and certain nonmalignant respiratory diseases. Mill workers suffering from renal cancer and other chronic renal disease including nephritis and kidney tubal tissue injury may also be eligible.
Ore Transporters
Like miners and mill workers, truckers who transported uranium ore may be eligible for a payment of $100,000. Claimants must have been employed for at least one year in the transport of uranium ore or vanadium-uranium ore from mines or mills located in Colorado, New Mexico, Arizona, Wyoming, South Dakota, Washington, Utah, Idaho, North Dakota, Oregon and Texas from January 1, 1942, until December 31, 1971. Compensable diseases include primary lung cancer, certain nonmalignant respiratory diseases, renal cancer and other chronic renal disease including nephritis and kidney tubal tissue injury.
Downwinders
A payment of $50,000 is available to individuals who were physically present in one of the affected areas downwind of the
Nevada Test Site during a period of atmospheric nuclear testing. Claimants must have lived or worked for a period of at least two years between January 21, 1951, and October 31, 1958, or from June 30, 1962, to July 31, 1962 in one of the following areas: the Utah counties of Beaver, Garfield, Iron, Kane, Millard, Piute, San Juan, Sevier, Washington and Wayne; the Nevada counties of Eureka, Lander, Lincoln, Nye, White Pine and that portion of Clark County that consists of townships 13 through 16 at ranges 63 through 71; or the Arizona counties of Apache, Coconino, Gila, Navajo, Yavapai and that part of Arizona that is north of the Grand Canyon. Diseases covered are leukemia (other than chronic lymphocytic leukemia), multiple myeloma, lymphomas (other than Hodgkin's disease), primary cancer of the thyroid or any of the following types of cancer: male or female breast, esophagus, stomach, pharynx, small intestine, pancreas, bile ducts, gall bladder, salivary gland, urinary bladder, brain, colon, ovary, liver (except if cirrhosis or hepatitis B is indicated) or lung.
Onsite Participants
Those who participated onsite in a test involving the atmospheric detonation of a nuclear device may be eligible for a payment of $75,000. A claimant must have been present above or within the official boundaries of the Nevada, Pacific, Trinity or South Atlantic Test Sites at any time during a period of atmospheric nuclear testing and must have participated during that time in the atmospheric detonation of a nuclear device. Diseases covered are leukemia (other than chronic lymphocytic leukemia), lung cancer, multiple myeloma, lymphomas (other than Hodgkin's disease), primary cancer of the thyroid, or any of the following types of cancer: male or female breast, esophagus, stomach, pharynx, small intestine, pancreas, bile ducts, gall bladder, salivary gland, urinary bladder, brain, colon, ovary, liver (except if cirrhosis or hepatitis B is indicated) or lung.
Comments